Hepatitis Drugs Market Analysis 2020 By Industry Drivers, Future Opportunities, Emerging Trends, and Global Forecasts To 2023

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Fri, 15 Jan 2021 07:20:13 / Comserve Inc. / — Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.

With COVID-19 resulting in the economic fallout, numerous economies are working on game-changing improvements to protect their employees and clients. While focusing on the ongoing challenges, the leaders are embracing new plans in order to manage and stay afloat in this competitive environment.

Overview:

Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-107197

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Key Players:

Gilead Sciences Inc.,
Abbvie Inc.,
Johnson & Johnson,
Merck & Co. Inc.,
GlaxoSmithKline plc,
Vertex Pharmaceuticals Inc.,
Novartis AG,
Hoffmann-La Roche Ltd., and
other predominate & niche players.

Market Analysis: The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017-2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.

Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.

The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.

Therapeutic Application Analysis: The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-107197

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Competitive Analysis:

At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 10
1.3 Pest Analysis 11
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Total Addressable Market (TAM) 14
3.2 Disease Overview 15
3.2.1 Hepatitis A 15
3.2.1.1 Epidemiology 15
3.2.1.2 Therapy 15
3.2.2 Hepatitis B 15
3.2.2.1 Epidemiology 15
3.2.2.2 Therapy 16
3.2.3 Hepatitis C 16
3.2.3.1 Epidemiology 16
3.2.3.2 Therapy 17
3.2.4 Hepatitis D 18
3.2.5 Hepatitis E 19
3.3 Disease Transmission 19
3.4 Related Markets 20
4 Market Outlook 21
4.1 Overview 21
4.2 Regulatory Bodies & Standards 21
4.3 Porter 5 (Five) Forces 22
5 Market Characteristics 23

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-107197

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count
Email: [email protected]
Tel: + 81 3 45720790

The post Hepatitis Drugs Market Analysis 2020 By Industry Drivers, Future Opportunities, Emerging Trends, and Global Forecasts To 2023 appeared first on Comserveonline.

COMTEX_377712368/2652/2021-01-15T07:33:11

Is there a problem with this press release? Contact the source provider Comtex at [email protected]. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.